[HTML][HTML] Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
Background Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
[PDF][PDF] Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
A Decock, M Ongenaert, J Hoebeeck, K De Preter… - 2012 - Citeseer
Background: Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
[引用][C] Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
A Decock, M Ongenaert, J Hoebeeck, K De Preter… - Genome …, 2012 - cir.nii.ac.jp
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic
methylation biomarkers | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
methylation biomarkers | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
[PDF][PDF] Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
A Decock, M Ongenaert, J Hoebeeck, K De Preter… - 2012 - backoffice.biblio.ugent.be
Background: Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
[PDF][PDF] Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
A Decock, M Ongenaert, J Hoebeeck, K De Preter… - 2012 - duepublico2.uni-due.de
Background: Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
A Decock, M Ongenaert, J Hoebeeck, K De Preter… - Genome …, 2012 - go.gale.com
Background Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
A Decock, M Ongenaert, J Hoebeeck, K De Preter… - Genome …, 2012 - europepmc.org
Background Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
[引用][C] Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
A DEROCK, M ONGENAERT, J HOEBEEK… - Genome …, 2012 - dial.uclouvain.be
[PDF][PDF] Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
A Decock, M Ongenaert, J Hoebeeck… - 2012 - pstorage-rcsi-9048708668.s3 …
Background: Accurate outcome prediction in neuroblastoma, which is necessary to enable
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …
the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma …